FREE DELIVERY ON ALL US ORDERS OVER $50 →
WHYZ Learn
← Back to NMN

NMN Benefits: 7 Evidence-Based Effects

Updated March 9, 2026 by WHYZ Editorial Team

Quick Answer

NMN supplementation reliably raises NAD+ levels by 40-50% and has shown benefits for insulin sensitivity, aerobic performance, and physical function in older adults. Evidence is promising but most trials are small and short-term.

Benefits Dosage FAQ How to Take Side Effects

NMN (nicotinamide mononucleotide) has been studied in over a dozen human clinical trials since 2020. The strongest evidence supports its ability to raise NAD+ levels, with emerging data on metabolic and physical performance benefits. Below are seven evidence-based benefits, ranked roughly by the strength of supporting evidence.

1. Restores Cellular NAD+ Levels

This is the most consistently replicated finding in NMN research. Every human trial that has measured blood NAD+ after NMN supplementation has found significant increases.

A multicenter, dose-dependent RCT enrolled 80 middle-aged adults and randomized them to 300, 600, or 900 mg/day of NMN or placebo for 60 days. All three NMN groups showed statistically significant increases in blood NAD+ at both 30 and 60 days (all p ≤ 0.001). The 600 mg and 900 mg groups achieved the highest concentrations (Yi et al., 2023). A 12-week Japanese trial confirmed that even 250 mg/day significantly elevated whole blood NAD+ (Okabe et al., 2022).

The MIB-626 pharmacokinetic study demonstrated that pharmaceutical-grade NMN at 1,000 mg daily produced substantial dose-related NAD+ increases, with very little unmodified NMN excreted in urine, indicating efficient metabolic conversion (Pencina et al., 2022).

Why this matters: NAD+ is required for over 500 enzymatic reactions, including energy metabolism, DNA repair, and sirtuin activation. NAD+ levels decline approximately 50% between ages 40 and 60. Restoring these levels is the mechanistic foundation for all of NMN’s proposed health benefits.

2. Improves Muscle Insulin Sensitivity

The strongest clinical finding for NMN comes from Washington University’s 10-week RCT published in Science. The study enrolled 25 postmenopausal women with prediabetes who were overweight or obese and gave them 250 mg/day NMN or placebo.

The NMN group showed increased insulin-stimulated glucose disposal measured by hyperinsulinemic-euglycemic clamp, the gold standard for assessing insulin sensitivity. Skeletal muscle biopsies revealed increased phosphorylation of AKT and mTOR, key nodes in the insulin signaling cascade. The NMN group also showed upregulation of genes related to muscle remodeling, including platelet-derived growth factor receptor β (Yoshino et al., 2021).

This study stands out because it used a hard clinical endpoint (clamp-measured insulin sensitivity) rather than surrogate biomarkers. The sample size was small (n=25) and limited to one population (postmenopausal women with prediabetes), so replication in larger and more diverse cohorts is needed.

3. Enhances Aerobic Exercise Performance

A six-week RCT randomized 48 amateur runners into four groups: placebo, 300 mg/day, 600 mg/day, or 1,200 mg/day NMN. All groups trained 5-6 times per week for 40-60 minutes per session.

The medium (600 mg) and high (1,200 mg) dose groups showed significantly greater increases in oxygen uptake at both the first and second ventilatory thresholds compared to placebo. Power output at these thresholds also increased in the NMN groups. The researchers attributed the improvement to enhanced O2 utilization in skeletal muscle. VO2max itself did not change significantly, suggesting NMN improves exercise efficiency rather than peak cardiovascular capacity (Liao et al., 2021).

For practical purposes, this means NMN may help you sustain higher intensity before hitting the “breathing hard” threshold during endurance exercise. The single-study evidence base limits the confidence of this claim, and the mechanism requires further investigation.

4. Supports Cardiovascular Health Markers

Two trials provide cardiovascular-relevant data:

The Katayoshi et al. 12-week trial (250 mg/day NMN, 36 participants) found a trend toward reduced pulse wave velocity, a measure of arterial stiffness, though the difference did not reach statistical significance (Katayoshi et al., 2023).

The Pencina et al. MIB-626 study (1,000 mg twice daily, 30 participants, 28 days) found more substantial cardiovascular effects: significant reductions in diastolic blood pressure (-7.01 mmHg difference vs. placebo), total cholesterol (-26.89 mg/dL), and LDL cholesterol (-18.73 mg/dL) (Pencina et al., 2023).

These findings are promising but require context. The MIB-626 study used a high dose (2,000 mg total daily) and had only 30 participants. Larger, longer trials are needed before NMN can be recommended specifically for cardiovascular protection.

5. Improves Physical Function in Older Adults

Aging-related decline in physical function is a major driver of lost independence. Two trials have tested NMN specifically in older populations:

Kim et al. (2022) enrolled 108 older Japanese adults and found that 12 weeks of NMN (250 mg/day) improved performance on the five-times sit-to-stand test, a validated measure of lower limb strength and function. The afternoon dosing group showed the largest improvement (effect size d = 0.72, considered a large effect). The same group also experienced reduced drowsiness scores (Kim et al., 2022).

The Yi et al. multicenter trial found that walking distance on the six-minute walk test increased significantly in all NMN-treated groups (300, 600, and 900 mg/day) compared to placebo at both 30 and 60 days, with the longest distances in the 600 mg and 900 mg groups (Yi et al., 2023).

6. May Reduce Body Weight and Improve Lipid Profile

The MIB-626 physiologic study found that 28 days of NMN supplementation at 1,000 mg twice daily resulted in a significant body weight reduction of 1.9 kg compared to placebo (p = .008). Non-HDL cholesterol and LDL cholesterol also decreased significantly (Pencina et al., 2023).

This finding is intriguing because the original mouse study by Mills et al. (2016) also showed that NMN suppressed age-associated weight gain over 12 months (Mills et al., 2016). However, the human finding comes from a single small trial at a high dose and has not been replicated. Other NMN trials at lower doses have not found significant weight changes. Label this as preliminary.

7. Supports Biological Age Markers

The Yi et al. trial included an exploratory measure of biological age using the Aging.Ai 3.0 calculator, which estimates biological age from blood biomarkers. Over 60 days, biological age increased significantly in the placebo group but remained stable in all three NMN-treated groups. The difference between treated groups and placebo was statistically significant (all p < 0.05) (Yi et al., 2023).

Biological age calculators are imperfect proxies for actual aging rate, and this was a secondary endpoint in a single trial. Nonetheless, the directional finding is consistent with NMN’s proposed mechanism of supporting cellular resilience through NAD+ restoration.

What NMN Has Not Been Proven to Do

Transparency about limitations matters. NMN has not been proven in human trials to:

  • Extend lifespan. No human longevity data exists. The anti-aging narrative is extrapolated from mouse studies.
  • Improve cognitive function. While NAD+ supports brain energy metabolism, no published RCT has demonstrated cognitive benefits from NMN supplementation.
  • Reverse aging. NMN may support cellular maintenance, but “reversing aging” is a marketing claim unsupported by human evidence.
  • Cure or treat any disease. NMN is a dietary supplement, not a pharmaceutical.

References

  1. Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults. Geroscience. 2023;45(1):29-43. PMID: 36482258

  2. Okabe K, Yaku K, Uchida Y, et al. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood nicotinamide adenine dinucleotide levels in healthy subjects. Front Nutr. 2022;9:868640. PMID: 35479740

  3. Pencina KM, Lavu S, Dos Santos M, et al. MIB-626 increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults. J Gerontol A Biol Sci Med Sci. 2023;78(1):90-96. PMID: 35182418

  4. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596

  5. Liao B, Zhao Y, Wang D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. J Int Soc Sports Nutr. 2021;18(1):54. PMID: 34238308

  6. Katayoshi T, Uehata S, Nakashima N, et al. NAD metabolism and arterial stiffness after long-term NMN supplementation. Sci Rep. 2023;13(1):2786. PMID: 36797393

  7. Pencina KM, Valderrabano R, Wipper B, et al. Nicotinamide adenine dinucleotide augmentation in overweight or obese middle-aged and older adults. J Clin Endocrinol Metab. 2023;108(8):1968-1980. PMID: 36740954

  8. Kim M, Seol J, Sato T, et al. Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults. Nutrients. 2022;14(4):755. PMID: 35215405

  9. Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806. PMID: 28068222

Written by WHYZ Editorial Team · Last updated March 2026

Not medical advice. Editorial policy →